Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weak Result Stops Pfizer’s Tremelimumab Phase III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.

You may also be interested in...



Intermediate Endpoint Proposals For Cancer Immunotherapies Don’t Sway FDA

An issue brief laying out four potential intermediate endpoints for checkpoint modulators draws a cautious response from FDA representatives at a cancer research conference. The endpoints may prove useful for exploratory purposes but are far from ready to serve as the basis for registration, agency says.

Pfizer Sets Its Sights On Therapeutic Cancer Vaccines

The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.

Pfizer Sets Its Sights On Therapeutic Cancer Vaccines

The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.

Related Content

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel